• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Sci Transl Med . Historic 1994 influenza vaccine cohorts define breadth of antibody and B cell responses toward future influenza A and B viruses

tetano

Editor, Senior Moderator
Sci Transl Med


. 2026 Apr;18(843):eaea8621.
doi: 10.1126/scitranslmed.aea8621. Epub 2026 Apr 1.
Historic 1994 influenza vaccine cohorts define breadth of antibody and B cell responses toward future influenza A and B viruses

Thi H O Nguyen[SUP] 1 [/SUP], Isabelle J H Foo[SUP] 1 [/SUP], Ruth A Purcell[SUP] 1 [/SUP], Hyon-Xhi Tan[SUP] 1 [/SUP], Georgia Deliyannis[SUP] 1 [/SUP], Wuji Zhang[SUP] 1 [/SUP], Louise Carolan[SUP] 2 [/SUP], A Jessica Hadiprodjo[SUP] 2 [/SUP], Howard H Huang[SUP] 1 [/SUP], Lilith F Allen[SUP] 1 [/SUP], Ruth R Hagen[SUP] 1 [/SUP], L Carissa Aurelia[SUP] 1 [/SUP], Hayley A McQuilten[SUP] 1 [/SUP], Louise C Rowntree[SUP] 1 [/SUP], Lukasz Kedzierski[SUP] 1 [/SUP], Samuel H Wilks[SUP] 3 4 [/SUP], Matthew R McKay[SUP] 1 3 4 [/SUP], Gregory A Tannock[SUP] 5 [/SUP], Stephen J Kent[SUP] 1 6 [/SUP], Karen Laurie[SUP] 7 [/SUP], Annette Fox[SUP] 2 8 [/SUP], Steven Rockman[SUP] 1 7 [/SUP], Lorena E Brown[SUP] 1 9 [/SUP], Amy W Chung[SUP] 1 [/SUP], Adam K Wheatley[SUP] 1 [/SUP], Katherine Kedzierska[SUP] 1 9 [/SUP]


Affiliations
Abstract

Vaccination is the best way to combat annual influenza epidemics, yet the breadth of vaccine-induced humoral immunity toward decades of future differentially evolving influenza A (IAV) and influenza B (IBV) viruses is unclear. Using historic 1994 influenza vaccination cohorts of young and older adults, we defined antibody responses elicited by 1994 vaccination against future influenza strains spanning three decades of differentially evolving IAV and IBV strains. Quality of antibody responses and vaccine-induced and cross-reactive B cell memory responses were investigated. Vaccination increased antibody titers against all 1994 vaccine components in younger and older adults. Antibodies to future H1N1 strains were also detected across younger and older adults, including nonneutralizing hemagglutinin (HA) stem responses. Prominent boosting against earlier B/Yamagata/16/1988 and future Yamagata lineage strains was also observed, but antibody responses toward future rapidly evolving H3N2 strains were minimal. Systems serology revealed divergent antibody signatures between younger and older adults against future antigens. However, postvaccination responses were of high quality in both age groups. Cross-reactive HA-specific memory B cells induced by 1994 vaccination bound to vaccine and future H1 and IBV strains but exhibited minimal responses against H3. Group 1 cross-reactive H1/H5 stalk-specific responses also contributed to the overall H1 future response, whereas cross-reactive H3/H7 stalk-specific B cells were not detected. Our study provides insights into the breadth of vaccine-induced humoral immunity toward future influenza viruses over 30 years of influenza virus evolution, including newly emerging pandemic strains, and highlights the unmet need to optimize future vaccines strategies, especially for H3N2.


 
Back
Top